目的:观察米非司酮联合米索前列醇治疗子宫内膜不典型增生(AEH)的疗效及安全性。方法:68例AEH患者随机分为观察组与对照组各34例。观察组予以米非司酮片150 mg,每3 d一次,服用米非司酮片48 h后加用米索前列醇片0.6 mg;对照组予以甲羟孕酮片30 mg,qd。两组均以6d为1周期,连用12个周期,观察治疗前后子宫内膜厚度变化,比较两组疗效及药品不良反应。结果:治疗12周期后,两组患者子宫内膜厚度均较治疗前有改善(P<0.01),且观察组改善幅度明显优于对照组(P<0.01)。观察组临床总有效率明显优于对照组(P<0.05),且药品不良反应发生率低于对照组(P<0.05)。结论:米非司酮联合米索前列醇治疗AEH安全、有效。 Objective: To observe the efficacy and safety of mifepristone combined with misoprostol in the treatment of endometrial dysplasia (AEH). Methods: 68 patients with AEH were randomly divided into observation group and control group, 34 cases each. The observation group was given mifepristone 150 mg once every 3 days, taking mifepristone 48 h after adding misoprostol 0.6 mg, while the control group was given medroxyprogesterone 30 mg qd. Both groups were 6d for a cycle, once every 12 cycles, before and after treatment to observe changes in endometrial thickness, the two groups were compared efficacy and adverse drug reactions. Results: After 12 cycles of treatment, the thickness of endometrium in both groups was significantly improved (P <0.01), and the improvement in the observation group was significantly better than that in the control group (P <0.01). The total effective rate in the observation group was significantly better than that in the control group (P <0.05), and the incidence of adverse drug reactions was lower than that in the control group (P <0.05). Conclusion: Mifepristone combined with misoprostol in the treatment of AEH is safe and effective.